Publications by authors named "MARIE Deschaseaux"
Article Synopsis
- Accurate determination of the infectious window period (IWP) is crucial for assessing the residual risk of infections detected via individual-donation (ID) and minipool (MP) nucleic acid tests (NAT) compared to serology assays.
- The study assessed the sensitivity of two NAT systems (Procleix Tigris and cobas s 201) to estimate IWPs for HIV and HBV using seroconversion panels and mathematical modeling.
- Results showed that Tigris ID-NAT detected HIV RNA 2 days earlier than s 201 MP6-NAT, and both NAT systems significantly reduced the window-period times compared to traditional antibody assays.
Background: The operational and analytical performance of two automated triplex hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test (NAT) systems were compared in four screening laboratories of the French Blood Service.
Study Design And Methods: Two laboratories evaluated the Procleix Tigris system (Chiron/Gen-Probe) in individual donation (ID) format and two sites used the cobas s 201 system (Roche Molecular Systems) on minipools (MPs) of six donations. The analytical sensitivity, the specificity, and operational performance were compared.
Background: The Pall third-generation enhanced bacterial detection system (eBDS) was recently approved for detection of bacterial contamination in leukoreduced platelets (PLTs). The method is based on the measurement of the oxygen content as a marker for bacteria. eBDS incorporates major modifications including removal of the sample-set filter, modification of the culture medium, and incubation with agitation of the sample pouch.
View Article and Find Full Text PDFBackground: A new enzyme immunoassay based on the simultaneous detection of nucleocapsid proteins of hepatitis C virus (HCV) and anti-HCV (Monolisa HCV antigen-antibody Ultra, Bio-Rad) was evaluated as an alternative to nucleic acid testing (NAT) for the diagnosis of HCV infection during the window period in blood donations.
Study Design And Methods: The study included 107 sequential samples from 10 HCV seroconversion commercial panels; 81 samples were in the preseroconversion phase, and 26 were collected after seroconversion. All samples were tested with HCV antigen-antibody assay and the two minipool (MP) NAT procedures that are routinely used in France (transcription-mediated amplification in pools of 8 and COBAS AmpliScreen HCV test [Roche Diagnostic] in pools of 24 donations).
Background: The main objective of the implementation of NAT for the screening of blood-borne viruses was to compensate for the failure of serologic assays during the window period. Because this new screening procedure theoretically covers the entire period of infectivity, the necessity for maintaining serologic assays in blood screening strategy could become questionable.
Study Design And Methods: To investigate this issue, a panel of 35 samples has been studied by NAT.